Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Context Intermediate-risk prostate cancer consists of a highly heterogeneous group of
patients. Owing to this heterogeneity and variable prognoses, it is challenging to provide …

Abstract Background Decipher Biopsy is a commercially available gene expression
classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently …

Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

Background Personalized genomic classifiers have transformed the management of
prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the …

Early identification and management of prostate cancer completely changed with the
discovery of prostate-specific antigen. However, improved detection has also led to …

The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored
by active surveillance rather than undergoing immediate treatment. However, a subset of …

Genomic and transcriptomic data have been generated across a wide range of prostate
cancer (PCa) study cohorts. These data can be used to better characterize the molecular …

Simple Summary Recently, biomarkers have become a supplemental tool to aid in the
diagnosis and evaluation of prostate cancer. Numerous biomarkers are being developed …